Hepatic Complications
Hepatic Complications - Related Videos
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
0 Views •
Cited by 2 •
2017
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput strategy.
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
0 Views •
Cited by 10 •
2012
An optical system was developed to visualize hepatic microcirculation with FITC-labeled erythrocytes and to measure the partial pressure of oxygen in the microvessels with laser-assisted phosphorimetry. This method can be used to investigate physiological and pathological mechanisms by analyzing microvascular structure, diameter, blood flow velocity, and oxygen tension.
06:00
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
0 Views •
2025
We present a laparoscopic technique for anatomic S7+S8d resection with right hepatic vein transection, preserving the inferior right hepatic vein and segment S6. Relying on meticulous anatomical landmarks without intraoperative ultrasound, this approach offers a precise and parenchyma-sparing option for dorsally located right-liver tumors, particularly in settings with limited advanced navigation resources.
01:24
Healing II: Complications
0 Views •
2026
Complications during healing arise when tissue repair is altered by local or systemic factors. These changes involve abnormal collagen deposition, altered biomechanics, and reduced vascular supply, impairing restoration of normal structure and function.Loss of FunctionScar tissue differs significantly from the original tissue it replaces. In the skin, fibrosis lacks adnexal structures such as hair follicles, sebaceous glands, and sweat glands. Their absence reduces tactile sensitivity, impairs...
06:53
Selective Harvesting of Marginating-hepatic Leukocytes
0 Views •
Cited by 1 •
2016
Marginating-hepatic leukocytes exhibit unique characteristics and distinct immunological functions compared to other leukocyte populations. Here we describe a method for selective harvesting of this specific hepatic cell population, through forced perfusion of the liver of rats or mice. Marginating-hepatic leukocytes seem critical in determining susceptibility to hepatic-related diseases and metastases.
FAQs
Drug-related liver injury may follow several mechanisms rather than a single pathway. Direct cellular injury can damage liver tissue, while reactive metabolites can create harmful intermediates. Immune-mediated reactions involve an adverse immune response, and disruption of bile flow produces cholestatic effects. Distinguishing these mechanisms helps pharmacologists interpret different patterns of liver dysfunction.
The likelihood and severity of hepatic complications depend partly on drug dose, interactions with other medicines, and individual patient risk factors. These variables can alter exposure to a medication or increase susceptibility to injury. Pharmacologists therefore consider them when evaluating hepatotoxicity and when deciding whether dosing or treatment plans require adjustment.
Alanine aminotransferase and bilirubin provide complementary information during assessment of hepatic complications. Changes in alanine aminotransferase can signal liver injury, whereas bilirubin measurement helps evaluate impaired handling of bile-related products. Monitoring both biomarkers supports earlier recognition of adverse effects and helps clinicians assess whether a medication may be affecting liver function.
Monitoring begins with assessment of relevant biomarkers, particularly alanine aminotransferase and bilirubin, alongside review of dose, drug interactions, and patient risk factors. Pharmacologists use these findings to identify possible hepatotoxicity and follow changes over time. This approach can support early detection before dysfunction progresses to more serious outcomes such as liver failure.
Hepatic safety assessment informs drug development by revealing how candidate medicines may affect liver function and which factors influence that risk. Biomarker monitoring, evaluation of dose and interactions, and attention to patient susceptibility provide evidence for safer development decisions. These assessments can also guide individualized dosing strategies before broader patient use.
They become particularly important when biomarker changes suggest possible hepatotoxicity or when a patient has relevant risk factors, medication interactions, or dose-related concerns. Pharmacologists and clinicians can use this information to reconsider treatment choices and tailor dosing. Early recognition supports safer patient care and may reduce progression from enzyme abnormalities to severe liver dysfunction.